Current market catalysts

Pharvaris shares are trading higher after the company announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release tablet for the prevention of HAE attacks.

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Philip Morris Intl Raises Preliminary FY2026 Adj EPS Guidance from $8.26-$8.41 to $8.35-$8.50 vs $8.41 Est

Philip Morris Intl (NYSE:PM) raises preliminary FY2026 Adj EPS guidance from $8.26-$8.41 to $8.35-$8.50 vs $8.41 analyst estimate..

Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85

Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.

Philip Morris Intl Raises Preliminary Q3 Adj EPS Guidance from $2.20-$2.25 to $2.29-$2.34 vs $2.43 Est

Philip Morris Intl (NYSE:PM) raises preliminary Q3 Adj EPS guidance from $2.20-$2.25 to $2.29-$2.34 vs $2.43 analyst estimate..

Philip Morris Intl Raises Preliminary FY2026 GAAP EPS Guidance from $7.19-$7.34 to $7.28-$7.43 vs $7.75 Est

Philip Morris Intl (NYSE:PM) raises preliminary FY2026 GAAP EPS guidance from $7.19-$7.34 to $7.28-$7.43 vs $7.75 analyst estimate..

Oportun Appoints Bill Franklin As CFO, Effective September 8

Oportun (NASDAQ:OPRT), a mission-driven financial services company, announced that Bill Franklin has joined the Company as Chief Financial Officer, effective today, September 8, 2026. Franklin will lead Oportun's

Guardant Health shares are trading higher after the company announced the FDA approved Guardant360 CDx.

Nebius Just Became Palantir’s Preferred Sovereign AI Infrastructure Partner

Nebius (NBIS) stock jumps 3% premarket after partnering with Palantir (PLTR) for sovereign AI infrastructure. Technicals stay bullish.

AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html

IonQ shares are trading higher after the company announced it published the first complete, end-to-end fault-tolerant resource estimate for running Shor’s algorithm.

Roivant Sciences shares are trading higher after the company announced its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease met its primary endpoint.

8-K filing — GENERAL ELECTRIC CO (GE)

Filed: 2026-09-08 AccNo: 0000950142-26-002501 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

IonQ Says Research Paper Estimates 20,000-Physical-Qubit Quantum Computer Could Break Bitcoin's secp256k1 Elliptic Curve In Just Under 26 Days; Says On Track For Fault-Tolerant 10,000-Qubit System In 2027

Clearmind Medicine Says Yale University’s IRB Approves Initiation Of Patient Recruitment For Parts B And C Of Phase I/II Clinical Trial Evaluating CMND‑100

Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company" or "Clearmind"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of

enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate

enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from

8-K filing — GROUP 1 AUTOMOTIVE INC (GPI)

Filed: 2026-09-08 AccNo: 0001193125-26-384390 Size: 398 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — IonQ, Inc. (IONQ-WT)

Filed: 2026-09-08 AccNo: 0001193125-26-384388 Size: 228 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

IonQ Raises FY2026 Sales Guidance from $280.000M-$290.000M to $450.000M-$460.000M

IonQ (NYSE:IONQ) raises FY2026 sales outlook from $280.000 million-$290.000 million to $450.000 million-$460.000 million. This outlook includes the contributions of SkyWater Technology beginning on July 31, 2026, the

8-K filing — Pyxis Oncology, Inc. (PYXS)

Filed: 2026-09-08 AccNo: 0001193125-26-384386 Size: 266 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

D-Wave Secures up to $100 Million in US Funding

D-Wave Quantum Inc. (NASDAQ: QBTS) stock rebounds after finalizing $100M U.S. deal for next-gen quantum systems.

YYForce Announces Incorporation Of 70-30 Joint Venture Facadevision AI With Integral Cleaning For Drone, AI-Enabled Facade Inspection In Singapore; Expects Commercial Deployment To Begin Q3 2026

BioVie Announces Bezisterim Has Potential To Treat Parkinson's Disease; To Hold Talks With FDA Over Phase 3 Trial Design

BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of

8-K filing — NABORS INDUSTRIES LTD (NBR)

Filed: 2026-09-08 AccNo: 0001104659-26-105673 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — Philip Morris International Inc. (PM)

Filed: 2026-09-08 AccNo: 0001628280-26-060806 Size: 833 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Quantum Cyber Announces Acquisition Of Lambda Hyperplane 8-A100 AI Compute Cluster With Eight NVIDIA A100 GPUs For Swarm Operating System, Quantum Station; To Be Installed At Bridgeport, Connecticut Facility

Quantinuum Finalized $100M CHIPS Funding From U.S. Department Of Commerce

Quantinuum (Nasdaq: QNT), a leading quantum computing company, today announced it has finalized an agreement with the U.S. Department of Commerce's CHIPS Research and Development Office for $100 million in federal

Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER,

Seabridge Gold Announces Energization Of Treaty Creek Terminal Supporting KSM Project On August 27; Expects Facility Ready For Service By November 2026

GE Aerospace Inks $11.75B Deal To Acquire Consolidated Precision Products

GE Aerospace (NYSE:GE) announced today that it has signed an agreement to acquire Consolidated Precision Products (CPP), a leading manufacturer of highly engineered castings, from private investment firms Warburg Pincus